Dysregulated Mir34a/diacylglycerol Kinase Ζ Interaction Enhances T-cell Activation in Acquired Aplastic Anemia

Y. Sun,H. Li,Q. Feng,Y. Yu,X. Li,J. Peng
DOI: https://doi.org/10.18632/oncotarget.14046
2016-01-01
Oncotarget
Abstract:Acquired aplastic anemia is an idiopathic paradigm of human bone marrow failure syndrome, which involves active destruction of hematopoietic stem cells and progenitors by cytotoxic T cells in the bone marrow. Aberrant expression of microRNAs in T cells has been shown to lead to development of certain autoimmune diseases. In the present study, we performed a microarray analysis of miRNA expression in bone marrow CD3(+) T cells from patients with aplastic anemia and healthy controls. Overexpression of miR34a and underexpression of its target gene diacylglycerol kinase (DGK)zeta in bone marrow mononuclear cells were validated in 41 patients and associated with the severity of aplastic anemia. Further, the level of miR34a was higher in naive T cells from patients than from controls. The role of miR34a and DGK zeta in aplastic anemia was investigated in a murine model of immune-mediated bone marrow failure using miR34a-/-mice. After T-cell receptor stimulation in vitro, lymph node T cells from miR34a(-/-) mice demonstrated reduced activation and proliferation accompanied with a less profound down-regulation of DGK zeta expression and decreased ERK phosphorylation compared to those from wild-type C57BL6 control mice. Infusion of 5 x 10(6) miR34a(-/-) lymph node T cells into sublethally irradiated CB6F1 recipients led to increased Lin-Sca1(+)CD117(+) cells and less vigorous expansion of CD8(+) T cells than injection of same number of wild-type lymph node cells. Our study demonstrates that the miR34a/DGK zeta dysregulation enhances T-cell activation in aplastic anemia and targeting miR34a may represent a novel molecular therapeutic approach for patients with aplastic anemia.
What problem does this paper attempt to address?